Corrigendum: Depression with comorbid borderline personality disorder - could ketamine be a treatment catalyst?

Study at a glance

Abstract

• please read through all the templates before choosing • pick the most relevant text template(s) from the following page and delete all others.• edit the text as necessary, ensuring that the original incorrect text is included for the record, please see the below. • please do not use any extra formatting when editing the templates, and only modify the red text unless absolutely necessary • submit to Frontiers following the instructions on this page.When the original text contained incorrect information, to preserve the scientific record, please include that text when editing the below templates. For example:There was a mistake in the Funding statement, an incorrect number was used. The correct number is "2015C03Bd051.". The publisher apologizes for this mistake.The original version of this article has been updated.In the published article, there was a mistake in the Funding statement. The funding statement for the Key Development Project of the Department of Science and Technology was displayed as "2015CBd051". The correct statement is "Key Development Project of Department of Science and Technology (2015C03Bd051).'' Corrigendum on: Więdłocha M, Marcinowicz P, Komarnicki J, Tobiaszewska M, Dębowska W, Dębowska M, Szulc A. Depression with comorbid borderline personality disorder -could ketamine be a treatment catalyst? Front Psychiatry. 2024 Apr 29;15:1398859. doi: 10.3389/fpsyt.2024.1398859. PMID: 38742125; PMCID: PMC11089186.NOTE TO AUTHORSthis is only to correct when there was an error in the statement, not to add new data to the studythat will require the submission of an AddendumIn the published article, there was an error in the Conflict of Interest statement. The original Conflict of Interest statement was: 'The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.' It did not include all of the authors' affiliations and potential financial conflicts of interest.Two co-authors of the article (MW and PM) were employed by KeyClinic -a commercial mental health center which provides ketamine treatment, as one of many services. The center offers multiple psychiatric and psychotherapeutic services and does not focus on ketamine treatment or market it in any way. Moreover one of the authors (AS) was employed by MindHealth (a commercial psychiatric center), was a member of Janssen Cilag Advisory Board and gave lectures for Janssen Cilag.The correct Conflict of Interest statement appears below.[Magdalena Więdłocha and Piotr Marcinowicz] were employed by [KeyClinic]. [Agata Szulc] was employed by [MindHealth], was a member of Janssen Cilag Advisory Board and gave lectures for Janssen Cilag. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.